Pradaxa User Wins $542K Verdict In Conn. Bellwether Trial
A Connecticut jury on Friday handed Boehringer Ingelheim Pharmaceuticals its first loss in several bellwether trials in a consolidated proceeding over the alleged bleeding risk of its blood thinner Pradaxa, finding...To view the full article, register now.
Already a subscriber? Click here to view full article